



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁵ : A61K 9/16	A1	(11) International Publication Number: WO 93/18753 (43) International Publication Date: 30 September 1993 (30.09.93)
(21) International Application Number: PCT/SE93/00225 (22) International Filing Date: 16 March 1993 (16.03.93) (30) Priority data: 9200858-0 20 March 1992 (20.03.92) SE (71) Applicant (for all designated States except US): KABI PHARMACIA AB [SE/SE]; S-751 82 Uppsala (SE). (72) Inventors; and (75) Inventors/Applicants (for US only) : KRISTENSEN, Henning, G. [DK/DK]; Viekaer 12 B, DK-2950 Vedbaek (DK). SCHAEFER, Torben [DK/DK]; Kalvehaven 7, DK-4330 Hvalsø (DK). THOMSEN, Lars, Juul [DK/DK]; Vognmandsmarken 70, DK-2100 Copenhagen (DK). KRISTENSEN, Arne [SE/SE]; Askvägen 22 A, S-756 53 Uppsala (SE).		(74) Agents: BERGANDER, Håkan et al.; Kabi Pharmacia AB, S-751 82 Uppsala (SE). (81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: PROCESS FOR THE PREPARATION OF SUSTAINED RELEASE PELLETS		
(57) Abstract A process for the manufacture of sustained release pellets comprising pelletizing a mixture containing the drug in finely divided form and a binder. The characteristic feature is that: (a) said binder is in particle form consisting of one or more water-insoluble wax-like binder substance(s) with a melting point above 40 °C, and (b) said pelletization step is performed by mechanically working said mixture, in a high shear mixer, under the input of a sufficient amount of energy for the binder to melt and pelletization to take place.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CJ	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

PROCESS FOR THE PREPARATION OF SUSTAINED RELEASE PELLETS.

TECHNICAL FIELD OF THE INVENTION.

The present invention relates to the manufacture of
5 pellets having defined and sustained release characteristics
and their multiple unit dose formulations.

The term "pellets" will forthcomingly refer to spherical
or spheroidal particles having diameters ranging from
0.2-2.5 mm.

10 By "multiple unit dose formulation" is contemplated an
oral dose formulation that at the appropriate location in the
gastrointestinal tract, usually the stomach or intestines
makes available a high number of similar units (e.g. pellets
or granules).

15

DESCRIPTION OF THE PRIOR ART.

In the field of pharmaceutical development, it is
generally agreed that the oral administration of a multiple
unit dose formulation possessing a sustained release of the
20 drug substance is beneficial compared to conventional tablet
formulations having similar release properties. The benefits
of multiple unit dose formulations are primarily that the
transport and distribution of the free units in the various
segments of the gastrointestinal tract are more uniform and
25 reproducible than single unit dosage forms.

With respect to tablets one has successfully obtained the
desired release properties by coating the tablets with wax-
like substances or mixes thereof, or by embedding the drug
substance in a matrix of binder of different degree of
30 hydrophilicity/hydrophobicity, if necessary together with
auxiliary substances like fillers, buffering substances etc.

With respect to granulation/pelletization of powdery drugs
the more common techniques are:

A fourth objective has been to provide pellets complying with the characteristics given further below in this specification.

5 THE INVENTION.

The invention aims at counteracting the disadvantages of the prior art granules/pellets and is a method for the manufacture of sustained release pellets containing a drug. The invention also encompasses multiple unit dose
10 formulations containing the pellets. The method comprises pelletizing a mixture containing the drug in finely divided form together with a binder and other auxiliary substances, such as fillers etc.

The characteristic features of the method and benefits of
15 the pellets produced are mainly attributed to the pelletization step. The inventive method is thus primarily characterized in that

- (a) said binder is particulate and contains one or more water-insoluble wax-like binder substances with a
20 melting point above 40°C, and
- (b) said pelletization is performed by mechanically working, in a high shear mixer, the mixture under input of a sufficient amount of energy for the binder to melt and the pelletization to take place.

25 The pellets may after having been formed be subjected to sieving in order to remove pellets of sizes above and below predetermined limits, and then portioning the remaining pellets into dose units. By the term dose unit is intended the amount of pellets placed in a capsule, tablet, sachet,
30 blister pack etc.

A general description of suitable high shear mixers is given in US 5,030,400 that is incorporated by reference.

Normally they are round-bottomed or flat-bottomed bowls with a mixer device containing a designated impeller or mixing
35 blade rotating about a central shaft close to the bottom and possibly also following the lower portion of the lateral walls of the bowls. In addition these mixers may also have a so-called chopper, i.e. fast rotating arms or knives

projecting into the bowl. In order to provide the appropriate energy input to the agitated mass, the rotation speed of the impeller is normally adjustable to more than 100 rpm and of the chopper to more than 1500 rpm. The upper limit of the rotation speed for the impeller is dependent on the production volume, e.g. to be less than 2000 rpm for laboratory scale mixers and less than 800 rpm for production scale mixers. For the chopper the rotation speed is usually less than 3000 rpm. In addition the bowl may have means for external heating or cooling.

In order to control the pelletization, the inner surface of the bowl should have a low adhesion for the agitated mixture. Thus in the most preferred variants of the invention the inner walls of the bowl, the impeller and any other means being in contact with the agitated mass must be coated with an inert polymer having low adhesion for the binder, drug etc. It has been found that polyfluorethylene polymers (Teflon) of the appropriate wear resistance are close to perfect. Too low wear resistance will mean that the inappropriate adhesion properties will appear too soon.

Normally, a high shear mixer will provide the efficient energy input by mechanically working the mixture, meaning that external heating is not necessary. Improper heating may in many cases adversely affect the pelletization process. The ultimate result of the granulation process is particles of spherical or spheroidal shape (pellets) and uniform size in high yields. The drug becomes embedded in a matrix of wax-like substances and, optionally, together with other excipients. For instance the method can be controlled to the formation of pellets having a predetermined mean diameter within 0.2 - 2.5 mm, preferably 0.5-2.0 mm, and with at least 75 % (w/w, yield) of the pellets within +/- 25% or within +/- 50%, preferably within +/- 0.35%, of said predetermined mean diameter. Thus the inventive pellets may be obtained in uniform size with a geometric standard deviation of 1.4 or less. The spheres formed are often characterized by a low porosity that increases inwards the spheres. The total pore

volume may be beneath 8 % or even beneath 5% in relation to the volume of the spheres.

The drug may be soluble or insoluble in water, with preference for drugs having a solubility that is higher than 1:100 in water buffered to pH = 7. Its melting point should be above the melting point for the binder, for instance more than 20-30°C above the melting point of the binder. In most cases the melting point of the drug is above 120°C or even above 140°C. The drug shall be in solid particulate form at the temperature used in the inventive process. The particle size of the drug may be within the range contemplated for conventional granulation/pelletization processes, which means within 1-200 μm , in particular 5-100 μm . Thus, the process is applicable even to cohesive drug substances. Depending on the potency of the drug, the release rate desired and the process parameters used for manufacturing the pellets, the drug content may vary between 1-90% of the final pellets (w/w), although in the normal situation the drug content is 20-80 % (w/w).

The present inventive process is of potential use for any drug that is to be administered orally in order to maintain predetermined blood levels throughout the day. Thus the drug may be bronchodilating, anti-inflammatory, antineoplastic, cytostatic, anti-conceptive, anti-coagulative, pain-releasing anesthetics etc and used in different fields such as urology, gynecology, autoimmunity, gastro enterology etc. Specific drugs to be mentioned are paracetamol, acetyl salicylic acid, morphin, theophylline, proxophylline, tranexamic acid, steroid hormones, omeprazol etc including, where appropriate, corresponding pharmaceutically and physiologically acceptable salts and prodrugs thereof, such as esters, which salts and prodrugs shall give rise to therapeutic effects.

Wax-like binder substances, including waxes as such, are well known in the galenic field and comprise natural, semisynthetic or synthetic plastic substances. The present invention may utilize wax-like substances that are termoplastic with melting points above +40°C, preferably above +45°, and below +120°C such as below +110°C.

Preferably, good wax-like thermoplastic substances have melting points 70-100°C. In case a wax-like substance of a melting point that is higher than 120° is possible to liquefy by simple mechanical working that substance may also be
5 useful in the present invention.

The binder may consist of one or more water-insoluble wax-like thermoplastic substance(s) possibly mixed with one or more wax-like thermoplastic substances being less hydrophobic than said one or more water-insoluble wax-like substances. To
10 meet the desire for constant release, it is believed that the individual wax-like substances in the binder should be substantially non-degradable and insoluble in gastrointestinal fluids under the relevant time frame and at least under the initial release phase.

15 Useful water-insoluble wax-like substances may have a water-solubility that is lower than about 1:5000 (w/w)

Potential binder substances are preferably water-insoluble with more or less pronounced hydrophilic and/or hydrophobic trends. Specifically the wax-like substance may comprise
20 fatty alcohols, fatty acids esters, fatty acid glycerides (mono-, di- and triglycerides), hydrogenated fats, hydrocarbons, normal waxes and hydrophobic and hydrophilic polymers having hydrocarbon backbones. A particularly useful hydrophobic water-insoluble wax-like substance is
25 microcrystalline wax, e.g. Petrolite 195 (Petrolite Corp., U.S.A.). Particularly useful wax-like substances with different degrees of hydrophilicity/hydrophobicity/lipophilicity are bees wax (pronounced lipophilic), glyceromonostearate (GMS), and sorbitan esters (for example
30 Span 60 having a melting point of 50°C and a HLB of 4.7).

In order to select wax-like substances having good thermoplastic pelletization properties, it is important to check them empirically as outlined in our experimental part. This depends on the knowledge with regard to critical
35 parameters of wax-like substances being deficient for the time being. However, it is believed that their hydrophobic/hydrophilic balance may be of importance as well as their viscosity and contact angle. One should look for suitable

thermoplastic wax-like substances among those having viscosity beneath 1000 cps at the pelletization temperature, e.g at 70°C, and a hydrophilic-lipophilic balance (HLB-value) lower than 5, preferably lower than 3.

- 5 In total the binder content may be in the range 10-90% (w/w/), such as 10-50% (w(w) with a preferred upper limit of 30% or 40% (w/w). In particular the preferred range is 15-25% (w/w).

10 The auxiliary substances (except the binder) used in connection with the invention are those commonly used in the field. For instance conventional fillers may be included, such as calcium hydrogen phosphate, lactose etc of the proper quality. Examples of other auxiliary substances are buffering substances and release rate increasing substances.

- 15 The pellets of the present invention is primarily intended for oral ingestion and passage through the gastrointestinal channel. The pH environment of ingested pellets changes during the passage. Because of this change, the solubility of the drug particles may change as well as the solubility and
20 stability of the filler and binder matrix. The effect of the varying solubility during passage through the gastrointestinal tract can be counteracted by addition of auxiliary substances having an acid or a basic character contributing to a buffered "micro-environment" in the
25 inventive pellets. This is a previously well known means to adjust the rate of release from tablets and granules. The same principle is applicable to the pellets of the present invention. Accordingly, basic substances like magnesium hydroxide and acidic substances like tartaric acid may be
30 included. The selection between a basic or an acidic buffering substance depends on the drug and where in the gastrointestinal tract the drug is to be released. In many cases fillers having the appropriate buffering capacity may act as a buffering substance.

- 35 The present process as such does not prohibit a burst effect. However, the burst effect may easily be counteracted by reduction of the pellet surface concentration of solid drug particles. This can be achieved by addition at a late

stage of the pelletization process of a water-insoluble hydrophobic wax-like thermoplastic substance as defined above. This additional wax-like substance is added as a finely divided powder at a process temperature which causes
5 melting of the substance and coating of the produced pellets. The wax-like substance used in this coating step may be between 1-10% of the total amount of ingredients added. Accordingly, pellets may be produced having an approximately constant release even from the very initial release stage.
10 Pellets produced according to the invention may also be coated in conventional ways.

In connection with previously known granules and tablets with sustained release, it is known that certain powder substances, such as talc, when located in the surface of
15 sustained release granules or tablets have an increasing effect of the overall release rate. One mode of the invention is therefore to balance the binder so that slightly overwettted pellets are formed during the mechanical working, and then, as out-lined by the prior art, in a second step add
20 a rate increasing compound as a fine powder and continue working so that the surfaces of the pellets become covered with the powder.

Dose units of the inventive pellets may be administered in those forms that are known for multiple unit dose
25 formulations, for instance as capsules (either enteric coated or non-coated), suspensions, sachets, tablets etc.

The invention is illustrated in the experimental part and is defined in the appending claims that are an integral part of the specification.

EXPERIMENTAL PART.Manufacture of the pellets

As pelletizing equipment a Pellmix pl 1/8 (Niro Atomizer,
5 Denmark) was used. The filler, drug and solid binder
consisting of wax-like binder substances were transferred to
the mixing bowl which may have been preheated. The powders
were mixed at approximately 1200 rpm until the product
temperature reached 90°C and the impeller speed was then
10 lowered to 500 rpm for calcium hydrogen phosphate-based
formulations and to 1000 rpm for lactose-based formulations.
The products were run for an additional period of 5-15
minutes allowing the pellets to form. Finally the products
were emptied out of the mixer, tray cooled and fractioned.

15 Binder substances used in our experiments were: Glyceryl
monostearate (=GMS), stearyl alcohol, stearic acid,
triglycerid (Danske Sukkerfabrikker, Denmark), beeswax,
microcrystalline wax (=MC-wax), all of which were wax-like
and thermoplastic (MC-wax was Petrolite 195 (Petrolite Corp.,
20 U.S.A.))

The results of the release experiments are represented
graphically in Figures 1-6.

Figure 1: The effect of binder type on release of
paracetamol.

25 Figure 2: The effect of binder composition on release of
paracetamol.

Figure 3: The effect of drug content on theophylline
release.

Figure 4: The effect of pH and filler solubility on
30 paracetamol release. CHP stands for calcium hydrogen
phosphate (CaHPO_4).

Figure 5: The effect on paracetamol release of adding a
meltable lipophilic powder.

Figure 6: The effect on paracetamol release on adding
35 talc.

EXAMPLE 1. Effect of binder type.

5	Composition:	CaHPO ₄	888g
		Paracetamol	120g
		Glyceryl monostearate (GMS)	96g
		Lipophilic binder substances	96g

The release of the 1000/um-1400/um fractions of the products were measured in an USP dissolution apparatus. Basket rotational speed was 100 rpm and the medium was 1000 ml Simulated Gastric Fluid, no enzymes (pH: 1.2).

10

Table 1 Effect of binder type on release of paracetamol.

		% Release					
Hours		0.66	1	2	4	6	8
Binder:							
15	GMS	50	62	81	97	100	100
	GMS+Stearyl alc.	29	35	49	68	79	87
	GMS+Stearyl acid	27	32	43	62	78	91
	GMS+Triglycerid DS	19	24	38	60	74	86
	GMS+Beeswax	20	23	31	47	61	72
20	GMS+MC-wax	19	21	26	34	41	47

The combination of GMS with lipophilic binders made it possible to modify the release rate. The GMS/MC-wax mixture showed relatively good sustained release properties (fig. 1).

25

EXAMPLE 2. Effect of the binder composition

30	Composition:	CaHPO ₄	888g
		Paracetamol	120g
		Binder	192g

The binder was either pure GMS, GMS/beeswax (3:1), GMS/beeswax (1:1) or GMS/beeswax (1:3).

Dissolution was measured as in Example 1.

Table 2 Effect of binder composition

Hours	% Release						
	0.66	1	2	4	6	8	
Binder:							
5	GMS	50	62	81	97	100	100
	GMS+Beeswax 3:1	28	33	47	67	81	92
	GMS+Beeswax 1:1	20	23	31	47	61	72
	GMS+Beeswax 1:3	11	13	16	21	25	29

10 As shown in table 2 and fig. 2 it was possible to modify the release profile by varying the composition of the binder.

EXAMPLE 3. Effect of drug content

Composition:	A	B	C
15 Theophylline	150 g	477 g	700 g
CaHPO ₄	850 g	323 g	0 g
GMS	96 g	80 g	76 g
MC-wax	89 g	75 g	71 g

The release rate was measured as in example 1.

20

Table 3 Effect of drug content

Hours	% Release						
	1	3	5	7	9	11	
Binder:							
25	Composition A	11	19	27	36	46	55
	Composition B	19	41	60	74	85	94
	Composition C	24	44	60	75	85	91

As shown in table 3 and fig. 3 the drug content could make
30 a total of up to approximately 80-90% of total pellet weight.

EXAMPLE 4. Effect of filler and pH of the dissolution medium.

35	Composition D:	CaHPO ₄	880g
		Paracetamol	120g
		GMS	99g
		MC-wax 195	93g

Composition E:	Lactose 450 mesh	880g
	Paracetamol	120g
	GMS	99g
	MC-wax 195	93

5 The release of paracetamol into simulated gastric fluid (pH 1.2) and simulated intestinal fluid (pH 7.5) was measured in analogy with the method given in example 1.

Table 4 Effect of filler and pH of the dissolution medium

		% Release (pH 1.2)						
10	Hours	0.33	0.66	1	2	4	6	8
	Composition D	19	23	25	29	35	40	45
	Composition E	47	77	90	99	100	100	100
		% Release (pH 7.5)						
15	Hours	0.33	0.66	1	2	4	6	8
	Composition D	15	17	20	25	34	42	48
	Composition E	44	72	86	97	98	100	100

As shown in table 4 and in fig. 4, the release rate was highly dependent on the solubility of the filler (CaHPO₄, or lactose). The pH of the medium has only a minor effect on the release of paracetamol from the products D and E.

EXAMPLE 5. Addition of a meltable lipophilic powder.

25	Composition:	F	G
	CaHPO ₄	648 g	648 g
	Paracetamol	360 g	360 g
	GMS	48 g	48 g
	Beeswax	144 g	144 g
30	Precifac		approx. 5 g

The portion of Precifac (cetyl palmitate, Gatefossé, France, composition G) was added at the end of the pelletization phase whereafter the mixture was run for additional 30 seconds.

35 The release into simulated gastric fluid (pH 1.2) was measured in analogy with the method given in example 1.

Table 5 Effect of adding a meltable lipophilic powder

Hours	% Release in simulated gastric fluid						
	0.33	0.66	1	2	4	8	11
Composition F	17	19	21	25	37	41	46
5 Composition G	4	5	6	8	12	16	18

As shown in table 5 and fig. 5, a substantial decrease in initial as well as in overall release rate was achieved by adding a meltable lipophilic powder (Precifac).

10

EXAMPLE 6. Effect of the addition of talc.

Composition	H	I
CaHPO ₄	888 g	888 g
Paracetamol	120g	120 g
15 GMS	48 g	48 g
Beeswax	144 g	144 g
Talc		5 g

The talc portion was added after the pelletization phase for composition I, whereafter the mixture was worked for additional 30 seconds. Talc addition increased the overall release rate without increasing the initial release.

The release of paracetamol in simulated gastric fluid (pH 1.2) was measured in analogy with the method given in example 1.

25

Table 6 Effect of adding talc

Hours	% Release (pH 1.2)						
	0.33	0.66	1	2	4	8	11
Composition H	10	11	13	16	21	29	34
30 Composition I	9	12	15	23	34	50	58

As shown in table 6 and fig. 6, the addition of talc increased the overall release rate without increasing the initial release rate.

35

C L A I M S

1. A process for the manufacture of sustained release pellets comprising pelletizing a mixture containing the drug in finely divided form and a binder, characterized in that
- 5 (a) said binder is particulate and consists of one or more water-insoluble wax-like binder substances with a melting point above 40°C, and
- (b) said pelletization step is performed by
- 10 mechanically working said mixture, in a high shear mixer, under the input of a sufficient amount of energy for the binder to melt and pelletization to take place.
2. A process for the manufacture of sustained release pellets according to claim 1, characterized in that
- 15 said pellets after being formed
- (i) is sieved thereby removing pellets of sizes above and below predetermined limits, whereafter
- (iii) the remaining pellets is portioned into dose
- 20 units.
3. A process for the manufacture of sustained release pellets according to any of claims 1-2, characterized in that a further portion of a wax-like binder
- 25 substance is added to the mixture after the pellets have been formed whereupon the working of the mixture is continued so that the wax-like substance of the further portion melts and coats the pellets.
- 30 4. A process for the manufacture of sustained release pellets according to anyone of claims 1-3, characterized in that the drug is intended for the treatment of a disease within the field of urology, gynecology, autoimmunity or gastroenterology.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6

1
INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 93/00225

A. CLASSIFICATION OF SUBJECT MATTER				
IPC5: A61K 9/16 According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED				
Minimum documentation searched (classification system followed by classification symbols)				
IPC5: A61K, B29B				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
SE,DK,FI,NO classes as above				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)				
WPI, WPIL, CLAIMS				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	US, A, 4132753 (BLICHARE ET AL), 2 January 1979 (02.01.79) --	1-4		
X	US, A, 4935246 (AHRENS), 19 June 1990 (19.06.90) --	1-4		
A	US, A, 5023089 (SAKAMOTO ET AL), 11 June 1991 (11.06.91) -- -----	1-4		
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.				
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;"> * Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; border: none; vertical-align: top;"> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family </td> </tr> </table>			* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family			
Date of the actual completion of the international search	Date of mailing of the international search report			
21 June 1993	28 -06- 1995			
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86	Authorized officer Anneli Jönsson Telephone No. +46 8 782 25 00			

INTERNATIONAL SEARCH REPORT
 Information on patent family members

28/05/93

International application No.
 PCT/SE 93/00225

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A- 4132753	02/01/79	NONE	
US-A- 4935246	19/06/90	DE-C- 3721721 EP-A,B- 0298355 SE-T3- 0298355	09/06/88 11/01/89
US-A- 5023089	11/06/91	EP-A,B- 0351580	24/01/90